Dysregulation of bone remodeling by imatinib mesylate

Effects of stem cell factor on osteoclast-like cell formation in long-term human marrow cultures

(2010) A. Demulder et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian α-carbonic anhydrase isoforms

(2009) Seppo Parkkila et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effects of imatinib mesylate in osteoblastogenesis

(2009) Daniele Tibullo et al.   EXPERIMENTAL HEMATOLOGY

Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib

(2009) H. Schmid et al.   HAEMATOLOGICA

Growth deceleration in a girl treated with imatinib

(2009) Tomiko Kimoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Role of the Osteoblast Lineage in the Bone Marrow Hematopoietic Niches

(2009) Joy Y Wu et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib

(2009) Susannah O'Sullivan et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Imatinib mesylate causes growth plate closure in vivo

(2009) K Vandyke et al.   LEUKEMIA

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

(2009) Jonathan A Winger et al.   BMC STRUCTURAL BIOLOGY

Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss

(2008) Helene François et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations

(2008) M. Cristofanilli et al.   ANNALS OF ONCOLOGY

Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice

(2008) David S. Margolis et al.   CALCIFIED TISSUE INTERNATIONAL

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

(2008) S. Jonsson et al.   HAEMATOLOGICA

Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals

(2008) Toru Hiraga et al.   INTERNATIONAL JOURNAL OF CANCER

PDGF Receptor β Is a Potent Regulator of Mesenchymal Stromal Cell Function

(2008) Ayano Tokunaga et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate Cancer

(2008) Paul Mathew et al.   JOURNAL OF UROLOGY

Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty

(2008) Stefania Mariani et al.   LANCET

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

(2008) N Brownlow et al.   LEUKEMIA

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA

Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1

(2008) A Chase et al.   LEUKEMIA

Disorders Involving Calcium, Phosphorus, and Magnesium

(2008) Sharon M. Moe   PRIMARY CARE

Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin—mRNA in cell lines

(2007) Peter Wihlidal et al.   LEUKEMIA RESEARCH

Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib

(2006) Tasuku Mashiba et al.   JOURNAL OF BONE AND MINERAL RESEARCH